Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 15

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 15
---
 of the date on which the reverse stock split is approved by the Company’s stockholders, a reverse stock split of all of the outstanding shares of our common stock, at a ratio in the range of 1-for-2 to 1-for-25, with such ratio to be determined by the board of directors in its discretion and included in a public announcement Risk Factor Summary Our business is subject to numerous risks and uncertainties, including those highlighted in the section entitled “ Risk Factors” immediately following this prospectus summary, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business. In particular, the following considerations, among others, may offset our competitive strengths or have a negative effect on our business strategy, which could cause a decline in the price of shares of our common stock and result in a loss of all or a portion of your investment:

| ● | Petros’ consolidated financial statements have been prepared on a going concern basis; Petros must raise additional capital to fund our operations in order to continue as a going concern. |

| ● | Petros has incurred significant losses and may continue to experience losses in the future. |

| ● | Petros is in the early development stage of its platform with no revenues from its platform and has no operating history in the broad commercialization of such platforms for consumer use. |

| ● | Petros has defaulted on certain covenants included in the Promissory Note with Vivus that has resulted in the Obligations becoming immediately due and payable on the date of the Foreclosure Notice and the potential forfeiture of assets pledged as collateral under the Promissory Note. |

| ● | Any difficulties or delays in product engineering, regulatory compliance, sales or marketing could affect Petros’ future results. |

| ● | Petros’ technology may be viewed as relatively new or untested, which could result in regulatory delays or disruptions in the pathway to commercialization. |

5

| ● | If Petros fail to successfully initiate broad commercialization of, market and sell its platform cost-effectively, its sales, business, financial condition and results of operations will be negatively affected. |

| ● | Cyberattacks and other data security breaches could compromise its proprietary and confidential information, which could harm its business and reputation or cause it to incur increased expenses to address any such breaches. |

| ● | Because Petros is a small company with limited resources, it may be unable to attract qualified personnel. |

| ● | Rx-to-OTC switches are part of Pet